UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 13, 2016
VALERITAS HOLDINGS, INC.
(Exact name of registrant as specified in its charter)
| | | | |
| Delaware | | 333-198807 | | 46-5648907 |
(State or Other Jurisdiction of Incorporation) | | (Commission File Number) | | (I.R.S. Employer Identification Number) |
750 Route 202 South, Suite 600
Bridgewater, NJ 08807
(Address of principal executive offices, including zip code)
+1-908-927-9920
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)). |
On June 13, 2016, Valeritas Holdings, Inc. (the “Company”) issued a press release titled “Valeritas Announces Positive Results in Four Studies on V-Go® Disposable Insulin Delivery Device at ADA 2016”. A copy of the press release is filed as Exhibit 99.1 to, and incorporated by reference in, this report.
(d) Exhibits
| | |
| |
| 99.1 | | Press release issued by the Company on June 13, 2016 titled “Valeritas Announces Positive Results in Four Studies on V-Go® Disposable Insulin Delivery Device at ADA 2016”. |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | | |
| | | | VALERITAS HOLDINGS, INC. |
| | | |
| Date: June 13, 2016 | | | | By: | | /s/ John Timberlake |
| | | | Name: John Timberlake |
| | | | Title: Chief Executive Officer |
EXHIBIT INDEX
| | |
Exhibit
No. | | Description |
| |
| 99.1 | | Press release issued by the Company on June 13, 2016 titled “Valeritas Announces Positive Results in Four Studies on V-Go® Disposable Insulin Delivery Device at ADA 2016”. |
